Literature DB >> 18421057

Eosinophilia with FIP1L1-PDGFRA fusion in a patient with chronic myelomonocytic leukemia.

Victor Zota1, Patricia M Miron, Bruce A Woda, Azra Raza, Sa A Wang.   

Abstract

Entities:  

Mesh：

Substances：

Year:  2008        PMID： 18421057     DOI： 10.1200/JCO.2007.15.3841

Source DB:  PubMed          Journal:  J Clin Oncol        ISSN： 0732-183X            Impact factor:   44.544


× No keyword cloud information.
  4 in total

Review 1.  Preclinical and clinical experience with dasatinib in Philadelphia chromosome-negative leukemias and myeloid disorders.

Authors:  Srdan Verstovsek
Journal:  Leuk Res       Date:  2008-11-14       Impact factor: 3.156

Review 2.  [Treatment of adult acute lymphoblastie leukemia with eosinophilia and abnormality of PDGFRA by autologous hematopoietic stem cell transplantation and imatinib: one case report and literatures review].

Authors:  Yuanyuan Shi; Donglin Yang; Qingzhen Liu; Yi He; Rongli Zhang; Mingzhe Han; Sizhou Feng
Journal:  Zhonghua Xue Ye Xue Za Zhi       Date:  2015-10

3.  Quizartinib (AC220) is a potent second generation class III tyrosine kinase inhibitor that displays a distinct inhibition profile against mutant-FLT3, -PDGFRA and -KIT isoforms.

Authors:  Kerstin Maria Kampa-Schittenhelm; Michael Charles Heinrich; Figen Akmut; Hartmut Döhner; Konstanze Döhner; Marcus Matthias Schittenhelm
Journal:  Mol Cancer       Date:  2013-03-07       Impact factor: 27.401

4.  Discovery of imatinib-responsive FIP1L1-PDGFRA mutation during refractory acute myeloid leukemia transformation of chronic myelomonocytic leukemia.

Authors:  Shilpan Shah; Sanam Loghavi; Guillermo Garcia-Manero; Joseph D Khoury
Journal:  J Hematol Oncol       Date:  2014-03-27       Impact factor: 17.388
  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.